

## TECHNICAL DATA SHEET

### CyFlow™ DLL4 Purified Anti-Hu; Clone MHD4-46

**REF** CV046130

**For Research Use Only.**  
**Not for use in diagnostic or therapeutic procedures.**

### Specifications

<b>Antigen</b>	DLL4
<b>Alternative Names</b>	—
<b>Clone</b>	MHD4-46
<b>Clonality</b>	monoclonal
<b>Format</b>	Purified
<b>Host / Isotype</b>	Mouse / IgG1
<b>Species Reactivity</b>	Human
<b>Negative Species Reactivity</b>	—
<b>Quantity [Concentration]</b>	0.1 mg [ 1 mg/ml ]
<b>Immunogen</b>	Recombinant soluble human DLL4

### Specificity

The mouse monoclonal antibody MHD4-46 recognizes the extracellular domain of DLL4 (δ-like ligand 4) antigen, a type I transmembrane protein which plays an important role in vascular development.

#### Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany  
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: [info@sysmex-partec.com](mailto:info@sysmex-partec.com)

## Application

Based on published sources, this antibody is suitable for the following applications:

- Flow cytometry
- Functional assays

## Storage Buffer

The reagent is provided in phosphate buffered saline (PBS) solution, pH  $\approx$ 7.4, containing 0.1% (w/v) sodium azide.

## Storage and Stability

<b>Storage</b>	Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
<b>Stability</b>	Do not use after expiration date stamped on vial label.

## Background Information

DLL4 ( $\delta$ -like ligand 4) is one of five ligands of Notch receptors. It interacts with Notch1 and Notch4. DLL4 is up-regulated at sites of physiologic and pathologic angiogenesis, whereas its expression is low in most adult normal tissues. It is also highly expressed in human clear-cell renal carcinomas, bladder cancers, and breast cancers. Blocking the DLL4-Notch interaction seems to be a promising therapeutic approach.

## References

- Yamanda S, Ebihara S, Asada M, Okazaki T, Niu K, Ebihara T, Koyanagi A, Yamaguchi N, Yagita H, Arai H: Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade. *Blood*. 2009 Apr 9; 113(15):3631-9. < PMID: 19218547 >
- Oishi H, Sunamura M, Egawa S, Motoi F, Unno M, Furukawa T, Habib NA, Yagita H: Blockade of delta-like ligand 4 signaling inhibits both growth and angiogenesis of pancreatic cancer. *Pancreas*. 2010 Aug; 39(6):897-903. < PMID: 20182391 >
- Sekine C, Koyanagi A, Koyama N, Hozumi K, Chiba S, Yagita H: Differential regulation of osteoclastogenesis by Notch2/Delta-like 1 and Notch1/Jagged1 axes. *Arthritis Res Ther*. 2012 Mar 5; 14(2):R45. < PMID: 22390640 >

---

The Safety Data Sheet for this product is available at [www.sysmex-partec.com/services](http://www.sysmex-partec.com/services).

---

---

### Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany  
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: [info@sysmex-partec.com](mailto:info@sysmex-partec.com)

